ArticleMolecular biology reports2026
Royal jelly suppresses senescence-associated secretory phenotype in senescent human epidermal keratinocytes.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRoyal Jelly (RJ) is widely used in cosmetics for its beneficial skin effects, but its impact on cellular senescence remains unclear. Senomorphic agents that suppress the senescence-associated secretory phenotype (SASP) offer safe therapeutic strategies for skin aging. This study investigates the senomorphic effects of RJ on epidermal senescence. METHODS AND
resultsWe utilized an in vitro replicative senescence model of normal human epidermal keratinocytes, validating our findings with cells from chronologically aged adult donors, including a 75-year-old. Results demonstrated that RJ significantly suppresses multiple SASP factors, including interleukin (IL)-6 and C-X-C motif ligand (CXCL) family members, in both models without inducing cytotoxicity. Mechanistically, RNA-sequencing revealed that senescence upregulated pro-inflammatory factors via TNF-α and NF-κB signaling pathways. RJ acts as a multitarget senomorphic agent, inhibiting these senescence-activated pathways and reducing oxidative stress.
conclusionsRJ is a potent natural senomorphic agent capable of modulating complex SASP networks. It provides valuable insights into potential strategies for mitigating skin inflammation and preserving youthfulness.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.